top of page

Ulcerative Colitis

​​

​

  • AMGEN

       A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of                     Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis

       Study Record | Beta ClinicalTrials.gov

​

  • ABIVAX 106​

      A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for        induction treatment in subjects with moderately to severely active ulcerative colitis

      Study Record | ClinicalTrials.gov

       

  • JANSSEN DUET UC

       A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and             Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely         Active Ulcerative Colitis​

      A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis - Full Text View - ClinicalTrials.gov 

       

Crohn's Disease

​​

​

  • Boehringer Ingelheim 1425-0003

       A Phase IIa, randomised, double-blind, placebo-controlled trial to evaluate the safety, efficacy, pharmacokinetics and                                           pharmacodynamics of BI 706321 orally administered for 12 weeks in patients with Crohn's Disease (CD) receiving ustekinumab                          induction treatment 

      A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease - Full Text View - ClinicalTrials.gov

​​

​

  • JANSSEN DUET CD

         A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and                 Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely             Active Crohn’s Disease​

       A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease - Full Text View - ClinicalTrials.gov

  • TELAVANT  ​

       A Phase 2, Multicenter, Double-blind, Two-arm Study of Subcutaneous RVT-3101 for the Treatment of Subjects with Moderate to Severe              Active Crohn’s Disease

Study Details | RVT-3101 for the Treatment of Moderate to Severe Active Crohn's Disease | ClinicalTrials.gov

​

  • Takeda COMPASS-CD                                                                                                                                                    A Phase 4 Study Evaluating Real-World Use of CDPATH™, a Crohn’s Disease Risk Prediction Tool

      A Study of CDPATH™ to Help Manage and Treat Crohn's Disease - Full Text View - ClinicalTrials.gov

​

​

​

​​

bottom of page